G1 Therapeutics, Inc.

Pharmacosmos Group and G1 Therapeutics announce successful closing of tender offer: https://bit.ly/3MTWtB2

Today is World Suicide Prevention Day; let's all work together to prioritize mental health and change the narrative on suicide to encourage open conversation and raise awareness that it can be prevented. Read more here: https://bit.ly/3MEEZc4

Throughout the month of September we join families, HCPs, and all companies involved in cancer research in recognizing Childhood Cancer Awareness Month. We can't stop until no child - anywhere - dies from cancer. https://bit.ly/3XvIs2V

Hematopoietic stem and progenitor cells - HSPCs - are the source of all blood cell lineages. Chemotherapy can damage your HSPCs, leading to multiple consequences. Learn about those consequences here. https://bit.ly/4g40rEB

Myelosuppression, a decrease in bone marrow activity resulting in reduced production of blood cells, is a common side effect of cytotoxic therapies like chemotherapy. Severe myelosuppression, called myeloablation, can be fatal.

Did you know that about two-thirds of people who receive a small cell #lungcancer diagnosis are already in extensive stage? Learn more about treatments for small cell lung cancer here.?https://bit.ly/3yz7eFF

We announced our financial results and business updates for the second quarter of 2024 this morning via press release. Read more here: https://bit.ly/3ytz8mo

We are excited to announce that G1 has entered into a definitive agreement to be acquired by Pharmacosmos for approximately $405 million. The combined company will be able to optimize the commercial reach to oncologists and expand the availability of our myeloprotection drug among patients living with ES-SCLC. G1 brings a well-established and successful commercial, sales, and medical platform to Pharmacosmos, who has complementary expertise in commercializing hematology and supportive care products a robust global commercial presence. For more information, please read our press release and other important information regarding the proposed transaction here:?https://bit.ly/46zgk1H

We are excited to announce that G1 has entered into a definitive agreement to be acquired by Pharmacosmos for approximately $405 million. The combined company will be able to optimize the commercial reach to oncologists and expand the availability of our myeloprotection drug among patients living with ES-SCLC. G1 brings a well-established and successful commercial, sales, and medical platform to Pharmacosmos, who has complementary expertise in commercializing hematology and supportive care products a robust global commercial presence. For more information, please read our press release and other important information regarding the proposed transaction here:?https://bit.ly/46zgk1H

Today we recognize World Lung Cancer Day. We stand with patients, families, providers, partners, and industry to focus on the power of unity in the fight against #LungCancer and the importance of early screening. Learn more here: https://bit.ly/3yq8sD1 #WLCD24